Trial reportThe American journal on addictions
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.
Trial report in The American journal on addictions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.The pharmacogenomics journal · 2020Trial
- Korean red ginseng complex accelerates alcohol metabolism and relieves hangover symptoms in Humans: A randomized, double-blind, placebo-controlled crossover clinical trial.Journal of ginseng research · 2026Article
- Effects of Plant-Based Extract Mixture on Alcohol Metabolism and Hangover Improvement in Humans: A Randomized, Double-Blind, Paralleled, Placebo-Controlled Clinical Trial.Journal of clinical medicine · 2023Article
- Genetic Vulnerability to Opioid Addiction.Cold Spring Harbor perspectives in medicine · 2021Review
- Pharmacotherapies and personalized medicine for alcohol use disorder: a review.Pharmacogenomics · 2020Review
- On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications.Expert review of precision medicine and drug development · 2020Article
- Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation.Journal of substance abuse treatment · 2019Article
- Pharmacogenetics of alcohol use disorder treatments: an update.Expert opinion on drug metabolism & toxicology · 2019Review
- Placebo effects and the molecular biological components involved.General psychiatry · 2019Review
- Treatment for Alcohol Use Disorder: Progress in Predicting Treatment Outcome and Validating Nonabstinent End Points.Alcoholism, clinical and experimental research · 2018Article
- Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.The American journal on addictions · 2017Review
- Network analysis of the genomic basis of the placebo effect.JCI insight · 2017Article
- Natural Products for the Prevention and Treatment of Hangover and Alcohol Use Disorder.Molecules (Basel, Switzerland) · 2016Review
- The placebo effect: From concepts to genes.Neuroscience · 2015Review
- Genetics and the placebo effect: the placebome.Trends in molecular medicine · 2015Review
- The pharmacogenetics of alcohol use disorder.Alcoholism, clinical and experimental research · 2015Review
- Advances in Medications and Tailoring Treatment for Alcohol Use Disorder.Alcohol research : current reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDisulfiram and naltrexone were evaluated in treatment of individuals with co-occurring alcohol dependence and other Axis I disorders (e.g., Major Depression). We explored pharmacogenetic interactions in genotyped subjects.
methodsAlcohol dependent (AD) subjects received naltrexone alone, placebo alone, disulfiram with placebo or disulfiram with naltrexone. They were genotyped for OPRM1 rs1799971 (Asn40Asp), and DBH rs1611115 (C-1021T). N = 107 male European-American subjects were included.
resultsThere were no significant interactions with OPRM1. DBH interacted with naltrexone on the primary outcome of abstinence from heavy drinking (χ(2) (1) = 5.23, p = .02). "T" allele carriers on naltrexone had more abstinence compared to "CC" subjects on naltrexone (FET, p = .01). "T" allele carriers on naltrexone had the highest overall rates of abstinence from heavy drinking (>90%). Also, DBH genotype interacted with disulfram (F(1,17) = 7.52, p = .01) on drinks per drinking day with less drinking for subjects with the "CC" genotype than for T allele carriers on disulfiram.
conclusionsDBH*rs1611115*T associated with better response to naltrexone, while for those on disulfiram that drank, "CC" subjects drank less than T carriers. For rs1799971*G, we did not replicate findings from previous studies showing a more favorable response to NTX, possibly due to the small available sample. SCIENTIFIC SIGNIFICANCE: Genotyping rs1611115 may be useful in understanding inter-individual differences in AD treatment response. FUTURE DIRECTIONS: Further study of rs1611115 pharmacogenetics is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.